BMY · Full Picture

BRISTOL MYERS SQUIBB CO — the full picture

Trailing window · 2026-05-12 to 2026-08-10

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 61
    quote_verified
    U.K. drugmaker AstraZeneca and New Jersey-based Bristol Myers Squibb are reportedly in early-stage talks for a potential $400 billion merger.
  2. Regulatory Approval Milestones · Regulatory action & investigationsPriority 35
    1 forward row(s); quote_verified
    The U.S. FDA approved Replimune's drug Tudriqev in combination with Bristol Myers Squibb's Opdivo for a difficult-to-treat form of advanced melanoma.
  3. AI Drug Discovery Collaboration · Partnerships & JVsPriority 33
    1 forward row(s); quote_verified
    Schrödinger announced a strategic agreement with Bristol Myers Squibb to integrate Bunsen, Schrödinger's agentic AI co-scientist, into BMS's research operations.

Threads by pillar

Strategy & Portfolio Priority 63 · 2 threads

Legal, Regulatory & Policy Priority 35 · 1 thread